You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Open Standard for Display Agnostic 3D Streaming (DA3DS)

    SBC: Third Dimension Technologies LLC            Topic: AF16AT07

    The Air Force has identified a need for a display agnostic common streaming model for 3D data. Third Dimension Technologies (TDT) and Oak Ridge National Laboratory (ORNL) have formed a consortium to define a 3D streaming model based on open standards for Display Agnostic 3D Streaming (DA3DS). Two factors are driving this need. The first is the dramatic increase in the collection, storage and trans ...

    STTR Phase II 2017 Department of DefenseAir Force
  3. Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine

    SBC: 490 BIOTECH INC            Topic: 400

    Expressing humanized bacterial luciferase in stem cellsMoving beyond firefly luciferase toexpand the informational capacity of animal models for regenerative medicine Project Summary This Small Business Technology TransferSTTRPhase II project proposes to develop complementary autonomously bioluminescentautobioluminescentin vitro stem cell lines and in vivo small animal model systems that enable th ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Freeze Casting of Tubular Sulfur Tolerant Materials for Solid Oxide Fuel Cells

    SBC: MILLENNITEK, LLC            Topic: A14AT011

    Solid oxide fuel cells have long suffered from degradation due to impurities in the fuel and complexities associated with dissimilar materials and high operating temperatures.This degradation lowers the usable cell power output and requires ancillary equipment for fuel sulfur removal and reformation.A unique microstructure for the tubular anode will be produced using a novel freeze-casting techniq ...

    STTR Phase II 2017 Department of DefenseArmy
  5. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Commercial Development of Stabilized Cellular Diagnostics and Therapeutics to Lessen Logistical Burden on the Battlefield

    SBC: Greystone Pharmaceuticals, Inc.            Topic: ST031001

    Massive blood loss is the most common cause of death in potentially survivable battlefield casualties, yet no definitive medical innovations have been made for reducing these deaths in the past several decades. It is still highly impractical to carry large volumes of refrigerated blood into battle, and substantial research for developing blood substitutes and extending the durability and portabili ...

    STTR Phase II 2005 Department of DefenseDefense Advanced Research Projects Agency
  7. Software for the Design and Certification of Unitized Airframe Components

    SBC: VEXTEC Corporation            Topic: AF05T015

    This SBIR Phase I will demonstrate the feasibility for a unitized component structural design tool that allows for holistic risk assessment. The analysis will transform the FEA predicted stress (or strain) state into fully probabilistic assessment of uncertainty in geometry and loading throughout the component. Thereafter the design tool will conduct probabilistic microstructural damage accumulati ...

    STTR Phase I 2005 Department of DefenseAir Force
  8. Gene Expression and Diagnosis of Diabetes

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be nonspecific. A single test that could readily distinguish between an autoimmune and non-autoimmune disorder would allow physicians to focus efforts on the specific disease that affects the patient. This is critical for diabetes mellitus (DM), which has two subsets, Type I and Type II. The sub ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. High Purity Amphotericin B: A Safer Antimycotic in AIDS

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly for patients with human immunodeficiency infections (HIV). We are jointly developing a high purity amphotericin B (AmB HP) product for intravenous administration. The nominal purity of AmB HP is 95%; ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Realistic Phantom Series for OLINDA/EXM Version 2

    SBC: RADAR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The OLINDA/EXM code, which replaces the popular MIRDOSE code for calculating dose estimates in nuclear medicine applications, was given an exemption by the FDA on June 15, 2004 to be distributed as a medical device. The code will have a 3 year lifetime, and may be considered for re-release in June of 2007. The current code contains the traditional phantom typ ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government